- Surcharge Appealing to Limit Bank Size: Fed's Tarullo
- European Commission Objects to Sun Micro-Oracle Deal
- Obama Says Will Raise Currency Issue with China
- Can Apple Top Microsoft as Most Valuable Tech Firm?
- Buffett to Sell Stakes in Norfolk Southern, Union Pacific
- Cramer: 5 Stocks to Play the Next Bull Run
- Do You Know Your Coca-Cola Myths?
- Electronic Arts Beats Street, Announces 1,500 Job Cuts
- Time Is Here to Look at Overseas Stocks: Bill Gross
- Why Google is Paying $750 Million for Ad Mob
- Warren Buffett to Sell Stakes In Union Pacific & Norfolk Southern
- Nov. 9: Unusual Volume Leaders
- The Battered Businesses Behind Housing
- Modern Warfare 2's Record-Breaking Launch
- Merck’s Mega-Monday Morning
- Why are Traders Bullish on This Food Company?
- Profiting From Natural Gas: Strategists
- S&P Stocks Trading at New 52-Week Highs
MOST SHARED
- Future of Marketing
- Oil Tomorrow
- Dow Up Over 100 After G20 Stimulus Pledge
- Obama Says Will Raise Currency Issue with China
- Priceline Crushes Profit Forecasts; Shares Jump
- Can Apple Top Microsoft as Most Valuable Tech Firm?
- Maria's Market Message
- A Year on, China's Stimulus Postpones its Problems
- Trial of Ex-Bear Stearns Managers Goes to Jury
Text Size 
Roche's $43.7 billion offer to buy Genentech may not be the last one, Birgit Kulhoff, pharmaceuticals analyst at Rahn & Bodmer told CNBC Monday.
Swiss-based pharmaceutical company Roche, which already owns 55.9 percent of Genentech [DNA
Loading...
()
], is offering $89 per share to buy up the remaining stake, a 9 percent premium to the biotech company's closing share price on Friday.
"I think for Roche this proposed deal at least at the current terms is positive, for Genentech I think they probably will not be too happy because it really gives rather low valuation to Genentech," Kulhoff told "Worldwide Exchange." "I think we might see higher bids in the end."
A combined entity would have a bigger marketing clout, would cooperate better in research and development and would lower costs, she said.
"In the end it could make sense, but of course that all depends on the price," Kulhoff said.
RELATED LINKS
It will be very important for Roche to maintain the culture of research and development at Genentech and to keep the innovation there going, she added.
Consolidation might continue with pharmaceutical companies buying biotech firms, as the valuations of biotech companies are still reasonable, Kulhoff said.
"That could be the start of a bigger M&A wave," she added.
Print
Email
- Do free market libertarians really believe what they say about ethics and shareholder value? The Big Money takes a look.
- Cramer did the research and found eight stocks that lead the pack. Read on to get his top picks.
- On the anniversary of the fall of the Berlin Wall, many in the former Eastern Bloc recall communism fondly.
- Software, biotech firms, even banks are watching a particular Supreme Court argument today.
- From politicians to CEOs to companies, here's your chance to vote for the winners and losers of 2009.
- A new sinister Internet viruses can turn you into an unsuspecting collector of child pornography.
Data is a real-time snapshot *Data is delayed at least 15 minutes